| __timestamp | CRISPR Therapeutics AG | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 59644696 |
| Thursday, January 1, 2015 | 13403000 | 79541000 |
| Friday, January 1, 2016 | 31056000 | 98015000 |
| Sunday, January 1, 2017 | 35845000 | 103958000 |
| Monday, January 1, 2018 | 48294000 | 103654000 |
| Tuesday, January 1, 2019 | 63488000 | 128951000 |
| Wednesday, January 1, 2020 | 88208000 | 135799000 |
| Friday, January 1, 2021 | 102802000 | 149883000 |
| Saturday, January 1, 2022 | 102464000 | 220206000 |
| Sunday, January 1, 2023 | 76162000 | 265542000 |
| Monday, January 1, 2024 | 72977000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of CRISPR Therapeutics AG and Travere Therapeutics, Inc. over the past decade.
From 2014 to 2023, Travere Therapeutics consistently outpaced CRISPR Therapeutics in SG&A spending, with a notable increase of over 345% from 2014 to 2023. In contrast, CRISPR Therapeutics saw a more modest rise of approximately 1,390% during the same period. The year 2022 marked a significant peak for Travere, with expenses reaching nearly 220% of their 2014 levels, while CRISPR's expenses peaked in 2021, showing a slight decline thereafter.
This financial trajectory highlights the strategic investments and operational scaling of these companies, offering insights into their market positioning and growth strategies.
AbbVie Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and CRISPR Therapeutics AG
Operational Costs Compared: SG&A Analysis of Jazz Pharmaceuticals plc and Travere Therapeutics, Inc.
Comparing SG&A Expenses: Grifols, S.A. vs Travere Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing CRISPR Therapeutics AG and Rhythm Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Perrigo Company plc
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Dynavax Technologies Corporation
Selling, General, and Administrative Costs: CRISPR Therapeutics AG vs Supernus Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Amphastar Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Dynavax Technologies Corporation and Travere Therapeutics, Inc.
Taro Pharmaceutical Industries Ltd. or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?